Refine
Document Type
- Article (2)
- Doctoral Thesis (2)
Has Fulltext
- yes (4)
Is part of the Bibliography
- no (4)
Keywords
- - (2)
- Abiraterone (1)
- Biochemie (1)
- Biokatalyse (1)
- Chemotherapie (1)
- Chemotherapy (1)
- Chirale Amine (1)
- Cytoprotection (1)
- Docetaxel (1)
- Heat shock protein 27 (1)
Institute
Publisher
- MDPI (1)
- S. Karger AG (1)
Introduction: Inhibition of androgen synthesis by abiraterone acetate (AA) entails enhanced overall survival rates and clinical benefit for patients with locally advanced and metastasized prostate cancer (PC). The expression of heat shock protein 27 (HSP27) is generally associated with cytoprotection and was demonstrated to mediate chemoresistance under cytostatic therapy, for instance, docetaxel treatment. In this study, we investigated the impact of AA treatment on HSP27 expression and PC cell growth. Materials and Methods: HSP27 expression levels in docetaxel and AA-treated PC cell lines LNCaP and PC-3 were determined by SDS PAGE and Western blot analysis. Proliferation assays were performed using a CASY Cell Counter and Analyzer Model TT (Roche Applied Science). Results: Despite significantly increased HSP27 expression in PC cells incubated with docetaxel, Western blot analysis implicated a significant reduction of the cytoprotective HSP27 in AA-treated PC cells. Notably, HSP27 stably overexpressed in PC-3-HSP27 cells did not appear as an HSP27-mediated proliferation benefit in the presence of AA as shown in docetaxel incubation studies. Conclusion: In contrast to repeatedly demonstrated HSP27-driven chemoresistance related to chemotherapeutics, our results may constitute a broader molecular mode of action of AA chemotherapy. AA efficacy may exert an HSP27 suppressive role that goes beyond the primarily assumed inhibition of androgen biosynthesis.
Chiral amines represent high-value fine chemicals serving as key intermediate products in pharmaceutical, chemical and agrochemical industries. In the past decades, application of amine transaminases (ATAs) for stereoselective amination of prochiral ketones emerged to an environmentally benign and economically attractive alternative to transition metal-catalyzed asymmetric synthesis to afford optically pure amines at industrial scale. However, the restricted substrate scope of wild-type transaminases prohibited the conversion of particularly sterically demanding substrates, making protein engineering indispensable. The following thesis covers elaboration of a novel assay for transaminases (Article I) and identification and development of transaminase variants in order to achieve biocatalytic preparation of a set of pharmaceutically relevant model amines, ideally in optically pure form for both stereoisomers, preferentially using asymmetric synthesis and most preferably using isopropylamine as cost-efficient amine donor co-substrate (Article II-IV). The aforementioned target amines and the corresponding precursor ketones (see Scheme 4.1) were conceived and provided by the company F. Hoffmann-La Roche to attain suitable biocatalysts for a variety of potential intermediates for active pharmaceutical ingredients. Protein engineering of the transaminase scaffolds investigated in this thesis comprised: Initial screening for suitable starting enzyme scaffolds, structure-guided rational design of these scaffolds to enable bulky planar substrate acceptance, elaboration of a sequence motif, verification of the motif and preparative-scale asymmetric synthesis reactions (Article II). For non-planar and structurally different target substrates, namely spatially bulky or bi-cyclic bridged substrates, the transaminase variants were specifically refined and a different evolutionary route had to be pursued (Article III and Article IV). These results (Article II) represent not only the first successful endeavor to engineer a PLP-fold type I amine transaminase (commonly denoted as (S)-selective) for the conversion of highly sterically demanding substrates, but also generally expanded the scope of available fold type I amine transaminases by enzymes having a novel and exceptionally broad substrate spectrum. Aside from structure-guided rational protein engineering, as well non-rational methods, such as site-specific saturation mutagenesis or directed evolution, were applied for protein-engineering. In order to do so for all of the target compounds, a novel high-throughput solid phase activity assay for transaminases that was actually developed during the master thesis, was refined and published (Article I). In the context of this thesis, the same assay principle was as well adapted for quantification of specific activities in liquid phase (Article III). A comparison of different methodologies for developing agar plate assays and a detailed step by step protocol of our transaminase assay are illustrated in a book chapter.
Die zytostatische Behandlung mit Docetaxel ist die leitliniengerechte Therapie des fortgeschrittenen, kastrationsresistenten Prostatakarzinoms (PCa). Die Entwicklung von Resistenzen gegenüber Docetaxel bedeutet auf Grund fehlender Therapiealternativen häufig eine deutlich verschlechterte Prognose für den Patienten. In dieser Arbeit wurde das Hitzeschockprotein 27 (HSP27) als bedeutsamer Faktor für erhöhte Docetaxelresistenz in PCa-Zellen identifiziert. Eine hohe Expression von HSP27 korrelierte während der Docetaxelbehandlung mit einer geringeren Docetaxel-Sensitivität der Tumorzellen. Für die Vermittlung dieser Zytoprotektion war die dephosphorylierte Form des Proteins verantwortlich, während die Expression von phosphomimetischem HSP27 eine deutliche Reduktion des Zellwachstums zur Folge hatte. Die Inkubation mit Docetaxel resultierte in einer verstärkten Expression von HSP27 und einer raschen Phosphorylierung des Proteins. Auf die erhöhte HSP27-Phosphorylierung folgte anschließend eine stete Abnahme des phosphorylierten HSP27-Anteils an der weiterhin steigenden HSP27-Gesamtproteinmenge. HSP27 wird stimulusabhängig hauptsächlich von zwei Kinasen an drei für die Funktion ausschlaggebenden Serin-Resten phosphoryliert. Die Modulation der HSP27-Phosphorylierung durch Inhibition und Aktivierung weder von Proteinkinase D1 (PKD1), noch von Mitogen-aktivierter Proteinkinase (MAPK) p38 allein führte zu signifikant verändertem Tumorzellwachstum. Die simultane Aktivierung beider Kinasen jedoch resultierte in einer erheblich verringerten Zellzahl. Die Ergebnisse der vorliegenden Arbeit demonstrieren, dass als Antwort auf Docetaxel-Exposition vermehrt HSP27 exprimiert wird, welches in seiner dephosphorylierten Form die Resistenz gegenüber der zytostatischen Wirkung von Docetaxel erhöht. Somit könnte die Aktivierung der für die HSP27-Phosphorylierung verantwortlichen Kinasen möglicherweise zur Sensibilisierung von Tumorzellen gegenüber dem Zytostatikum Docetaxel führen. Dies würde eine zusätzliche Therapieoption für die Behandlung des fortgeschrittenen, kastrationsresistenten PCa eröffnen.
Non-invasive physical plasma (NIPP) achieves biomedical effects primarily through the formation of reactive oxygen and nitrogen species. In clinical use, these species interact with cells of the treated tissue, affecting the cytoplasmic membrane first. The present study investigated the permeability of the cytoplasmic membrane of breast cancer cells with different fluorescent dyes after NIPP treatment and determined the subsequent effects on cell viability. After NIPP treatment and the associated formation of reactive oxygen species, low molecular weight compounds were able to pass through the cytoplasmic membrane in both directions to a higher extent. Consequently, a loss of cellular ATP into the extracellular space was induced. Due to these limitations in cell physiology, apoptosis was induced in the cancer cells and the entire cell population exhibited decreased cell growth. It can be concluded that NIPP treatment disturbs the biochemical functionality of the cytoplasmic membrane of cancer cells, which massively impairs their viability. This observation opens a vast application horizon of NIPP therapy to treat precancerous and malignant diseases beyond breast cancer therapy.